drugset / Trial / NCT03812562
Nivolumab and Yttrium-90 in Treating Patients With Liver Cancer Undergoing Surgical Resection
Phase 0
Terminated
2 enrolled
Northwestern University
Bristol-Myers Squibb · collabNational Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
This early phase I trial studies how well nivolumab and yttrium-90 work in treating patients with liver cancer who are undergoing surgical resection. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body?s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Radioactive drugs, such as yttrium-90, may carry radiation directly to tumor cells and not harm normal cells. Giving nivolumab and yttrium-90 may work better in treating patients with liver cancer.
Timeline
- Start
- 2019-02-07
- Primary completion
- 2023-10-19
- Completion
- 2023-10-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nivolumab | Monoclonal antibody | — | Intravenous |
| Background | Yttrium Y 90 Glass Microspheres | Other / unclassified | — | Intravenous |